Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261950 · ClinicalTrials.gov registry record · Phase 2
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
A Phase 2 study of Secondary Hyperparathyroidism, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT00261950 is a Phase 2 study of Secondary Hyperparathyroidism that has completed, run by Amgen. The registered enrollment target is 110 participants, above the 51-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT00261950, a Phase 2 study of Secondary Hyperparathyroidism, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
Conditions Studied
Interventions
- DRUG Sensipar (Cinacalcet HCl)
Study Locations (20)
New York
- Research Site - Flushing
- Research Site - Great Neck
- Research Site - New York
- Research Site - The Bronx
Other
- Research Site - Antwerp
- Research Site - Antwerp
- Research Site - Brussels
- Research Site - Leuven
Arizona
- Research Site - Phoenix
California
- Research Site - Los Angeles
Colorado
- Research Site - Denver
Connecticut
- Research Site - New Haven
Florida
- Research Site - Fort Lauderdale
Illinois
- Research Site - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00261950
The ClinicalTrials.gov registry entry for NCT00261950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (116% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Sensipar (Cinacalcet HCl) is the first listed.
NCT00261950 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT00261950 about?
NCT00261950 is a clinical study titled "Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease". The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
What is the current status of trial NCT00261950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2006-05. Estimated completion is 2011-05.
What conditions does trial NCT00261950 study?
This clinical trial studies the following conditions: Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT00261950?
The interventions under investigation include: Sensipar (Cinacalcet HCl) (DRUG).
Who is sponsoring clinical trial NCT00261950?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00261950 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
COMPLETED · Phase 2
-
Precision Medicine Approaches to Renal Osteodystrophy
RECRUITING
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
-
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.